Access to bevacizumab, an important component of oncology treatment regimens, may be\nlimited. This survey of oncologists in the US (n = 150), Europe (n = 230), and emerging markets\n(EM: Brazil, Mexico, and Turkey; n = 130) examined use of and barriers to accessing bevacizumab as\ntreatment of advanced solid tumors. We also assessed the likelihood that physicians would prescribe\na bevacizumab biosimilar, if available. Bevacizumab was frequently used as early-line therapy in\nmetastatic colorectal cancer, metastatic non-squamous nonââ?¬â??small-cell lung cancer, and metastatic\novarian cancer (all markets), and as a second-line therapy in glioblastoma multiforme (US, EM).\nA greater percentage of EM-based physicians cited access-related issues as a barrier to prescribing\nbevacizumab versus US and EU physicians. Lack of reimbursement and high out-of-pocket costs\nwere cited as predominant barriers to prescribing and common reasons for reducing the number of\nplanned cycles. Overall, ~50% of physicians reported they ââ?¬Å?definitelyââ?¬Â or ââ?¬Å?probablyââ?¬Â would prescribe\na bevacizumab biosimilar, if available. Efficacy and safety data in specific tumor types and lower\ncost were factors cited that would increase likelihood to prescribe a bevacizumab biosimilar. A lower\ncost bevacizumab biosimilar could address the unmet needs of patients and physicians worldwide,\nand may have the greatest impact on patient outcomes in EM.
Loading....